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	 Sodium	 cromoglycate	 (SCG)	 and	 oxymetazoline	 hydrochloride	 (OXMT)	 are	 administered	 in
combination	 for	 effective	 treatment	 of	 nasal	 congestion	 and	 allergy.	 In	 this	 work,	 SCG	was
determined	using	direct	spectrophotometry	by	measuring	its	zero	order	absorption	spectra	at
its	 λmax	 320.6	 nm	 where	 OXMT	 showed	 zero	 absorbance.	 On	 the	 other	 hand,	 four	 simple,
sensitive	 and	 precise	 spectrophotometric	 methods	 were	 developed	 and	 validated	 for	 the
determination	 of	 OXMT	 in	 the	 presence	 of	 SCG	 in	 their	 laboratory	 prepared	 mixtures	 and
pharmaceutical	 formulation,	 without	 preliminary	 separation;	 Method	 A:	 first	 derivative
spectrophotometric	 method	 [1D],	 Method	 B:	 first	 derivative	 of	 ratio	 spectra	method	 [1DD],
Method	 C:	 ratio	 difference	 spectrophotometric	 method	 [RDSM]	 and	 Method	 D:	 ratio
subtraction	method	[RSM].	Ratio	manipulating	methods	(Method	B,	C	and	D)	were	done	using
divisor	of	10.00	µg/mL	SCG.	Linear	correlation	was	obtained	in	range	4‐22	µg/mL	for	OXMT
by	 methods	 A,	 B	 and	 D	 and	 6‐22	 µg/mL	 for	 method	 C.	 All	 methods	 were	 validated	 in
compliance	 with	 the	 International	 Conference	 on	 Harmonization	 (ICH)	 guidelines	 and
satisfactory	results	were	obtained.	No	significant	difference	was	noted	between	the	developed
methods	and	the	official	one	with	respect	to	accuracy	and	precision.	
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1.	Introduction	
	
Chemically,	 sodium	 cromoglycate	 is	 5,5′‐(2‐hydroxy	
propane‐1,3‐diyl)bis(oxy)bis(4‐oxo‐4H‐chromene‐2‐carboxylic	
acid)	 disodium	 salt	 (Figure	 1a).	 It	 exerts	 its	 action	 via	
preventing	 the	 release	 of	 mediators	 that	 would	 normally	
attract	inflammatory	cells	[1].	Oxymetazoline	hydrochloride	is	
chemically	 designated	 as	 3‐(4,5‐dihydro‐1H‐imidazol‐2‐
ylmethyl)‐2,4‐dimethyl‐6‐tert‐setyl‐phenol	 hydrochloride	 salt	
(Figure	1b).	It	is	a	sympathomimetic	agent	that	selectively	acts	
on	α1	and	partially	on	α2	adrenergic	receptors	[2].	Both	drugs	
are	co‐formulated	in	a	nasal	spray	dosage	form	and	are	widely	
used	 for	 effective	 treatment	 of	 nasal	 congestion	 and	 allergy.	
Several	methods	have	been	reported	for	the	determination	of	
SCG	 in	 pharmaceutical	 preparations	 such	 as	 spectrophoto‐
metry	 [3,4],	 electrophoresis	 [5],	 electrochemical	 [6,7]	 and	
HPLC	methods	[8‐14].	OXMT	has	also	been	analyzed	by	several	
methods	 in	 pharmaceutical	 preparations	 such	 as	 spectro‐
photometry	 [3,15‐23],	 capillary	 electrophoresis	 [24,25],	 gas	
chromatography	[26,27]	and	HPLC	[28‐35].	
 
	
Figure	 1.	 Chemical	 structures	 of	 (a)	 sodium	 cromoglycate	 (SCG) and	 (b)	
oxymetazoline	hydrochloride	(OXMT).	
	
To	 the	 best	 of	 our	 knowledge,	 Abdel‐Aziz	 et	 al.	 [3]	
developed	new	accurate,	sensitive	and	selective	spectrophoto‐
metric	 and	 spectrofluorimetric	methods	 for	 determination	 of	
SCG	 and	 OXMT.	 The	 aim	 of	 this	 study	 is	 to	 develop	 simple,	
accurate,	precise	and	time	saving	spectrophotometric	methods	
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for	 the	 routine	 analysis	 of	 SCG	 and	 OXMT	 in	 quality	 control	
laboratories	 either	 in	 their	 pure	 forms	 or	 in	 pharmaceutical	
formulations	with	no	prior	separation.	
	
2.	Experimental	
	
2.1.	Instrumentation	
	
A	 Shimadzu	 dual	 beam	 UV‐visible	 spectrophotometer,	
model	 1601	 PC	 connected	 to	 an	 IBM	 compatible	 personal	
computer	and	the	bundled	software,	UV‐PC	personal	spectros‐
copy	 software	 version	 (3.7)	 were	 used	 in	 all	 determinations	
(Shimadzu,	Kyoto,	Japan).	The	spectral	band	width	was	0.2	nm	
with	wavelength	scanning	speed	of	2800	nm/min.	
	
2.2.	Pure	samples	and	pharmaceutical	formulations	
	
SCG	pure	 sample	was	 supplied	by	 SIGMA	Pharmaceutical	
industries,	 Egypt.	 Pure	 sample	 of	 OXMT	 was	 supplied	 by	
National	 Organization	 for	 Drug	 Control	 and	 Research	
(NODCAR),	Egypt.	Their	purity	were	checked	and	found	to	be	
101.5±1.01	 and	 99.93±1.01	 for	 SCG	 and	 OXMT,	 respectively,	
according	 to	 the	 USP	 reference	 methods	 [36]	 which	 are	
spectrophotometric	 and	 HPLC	 methods	 for	 SCG	 and	 OXMT,	
respectively.	Nasocrom	®	nasal	spray	(SIGMA	Pharmaceutical	
industries,	Egypt),	 labeled	to	contain	2g	of	SCG	and	0.025g	of	
OXMT	per	100	mL	(Batch	number:	11087)	was	obtained	from	
the	local	market.	
	
2.3.	Standard	solutions	and	laboratory	prepared	mixtures	
	
Stock	standard	solutions	of	SCG	and	OXMT	(1.00	mg/mL)	
were	prepared	by	dissolving	100	mg	of	each	drug	 in	100	mL	
methanol.	Working	standard	solutions	of	SCG	and	OXMT	(0.10	
mg/mL)	 were	 prepared	 by	 diluting	 10	 mL	 from	 their	
respective	 stock	 standard	 solutions	 (1.00	 mg/mL)	 into	 two	
separate	 100‐mLvolumetric	 flasks	 and	 the	 volume	 was	
completed	 with	 methanol.	 Into	 a	 series	 of	 10mL	 volumetric	
flasks,	aliquots	of	SCG	and	OXMT	were	accurately	transferred	
from	 their	 corresponding	 working	 solutions	 and	 then	 the	
volumes	were	completed	to	 the	mark	with	methanol	 in	order	
to	 prepare	 mixtures	 containing	 different	 ratios	 of	 the	 two	
drugs.	
	
2.4.	Procedures	
	
2.4.1.	Spectral	characteristics	of	SCG	and	OXMT		
	
The	 absorption	 spectrum	 of	 10.00	 µg/mL	 of	 each	 of	 SCG	
and	 OXMT	 solutions	were	 recorded	 in	 the	wavelength	 range	
200‐400	nm	against	methanol	as	a	blank.	
	
2.4.2.	Construction	of	calibration	curves	
	
SCG:	Aliquots	 equivalent	 to	10.00‐250.00	μg	 of	 SCG	were	
accurately	 transferred	 from	 its	 working	 standard	 solution	
(0.10	mg/mL)	into	a	series	of	10	mL	volumetric	flasks	then	the	
volumes	 were	 completed	 to	 the	 mark	 with	 methanol.	 The	
absorption	 spectra	 of	 the	 prepared	 solutions	 were	 recorded	
against	 methanol	 as	 a	 blank	 (200‐400	 nm)	 the	 values	 of	
absorbance	of	SCG	at	its	λmax	(320.6	nm)	were	plotted	against	
their	 corresponding	 concentrations	 (1.00‐25.00	 µg/mL)	 and	
the	regression	parameters	were	computed.	
OXMT:	Aliquots	equivalent	to	10.00‐250.00	μg	OXMT	were	
accurately	 transferred	 from	 its	 working	 standard	 solution	
(0.10	mg/mL)	into	a	series	of	10mL	volumetric	flasks	then	the	
volumes	 were	 completed	 to	 the	 mark	 with	 methanol.	 The	
absorption	 spectra	 of	 the	 prepared	 solutions	 of	 OXMT	 were	
recorded	 against	 a	 blank	 of	 methanol	 and	 stored	 for	
subsequent	manipulation.	
	
2.4.3.	Method	A:	First	derivative	spectrophotometric	
method	[1D]	
	
The	first	derivative	(1D)	of	the	scanned	OXMT	spectra	was	
calculated	 (∆λ	 =	 8,	 scaling	 factor	 =10).	 A	 calibration	 curve	
representing	the	relation	between	the	amplitude	of	1D	at	289.2	
nm	 to	 the	 corresponding	 concentrations	 (4.00‐22.00	 µg/mL)	
was	constructed	and	the	regression	equation	was	computed.	
	
2.4.4.	Method	B:	First	derivative	of	ratio	spectra	method	
[1DD]	
	
The	stored	scanned	spectra	of	OXMT	(1.00‐25.00	µg/mL)	
were	 divided	 by	 a	 standard	 spectrum	 of	 SCG	 (10.00	 µg/mL)	
and	 1DD	 was	 then	 obtained	 (∆λ	 =	 8,	 scaling	 factor	 =1	 0).	 A	
calibration	 curve	 representing	 the	 relation	 between	 peak	
amplitude	 of	 1DD	 at	 292	 nm	 to	 the	 corresponding	
concentrations	 (6.00‐22.00	 µg/mL)	 was	 constructed	 and	 the	
regression	equation	was	computed.	
	
2.4.5.	Method	C:	Ratio	difference	method	(RD)	
	
The	stored	scanned	spectra	of	OXMT	(1.00‐25.00	µg/mL)	
were	 divided	 by	 a	 standard	 spectrum	 of	 SCG	 (10.00	 µg/mL)	
and	the	amplitude	of	the	ratio	spectra	at	286.6	and	294.0	nm	
were	 recorded.	 A	 calibration	 curves	 was	 constructed	 by	
plotting	the	difference	between	the	amplitude	ratio	difference	
(ΔP	 286.6‐294	 nm)	 versus	 the	 corresponding	 concentrations	
(4.00‐22.00	 µg/mL)	 and	 the	 regression	 equations	 were	
computed.	
	
2.4.6.	Method	D:	Ratio	subtraction	method	(RS)	
	
A	 calibration	 curve	 representing	 the	 relation	 between	
absorbance	of	OXMT	at	λmax	=	282.6	nm	to	the	corresponding	
concentrations	 (4.00‐22.00	 µg/mL)	 was	 constructed	 and	 the	
regression	equation	was	computed.		
	
2.4.7.	Analysis	of	laboratory	prepared	mixtures	
	
The	 absorption	 spectra	 of	 laboratory	 prepared	 mixtures	
were	 recorded	 and	 the	 procedures	 were	 performed	 as	
described.	 The	 concentrations	 of	 SCG	 and	 OXMT	 were	
calculated	using	the	corresponding	regression	equations.	
	
2.4.8.	Application	to	Nasocrom®	nasal	spray	and	standard	
addition	
	
Aliquots	 of	 0.5	 mL	 of	 Nasocrom	 nasal	 spray	 was	 mixed	
with	2.38	mg	OXMT	then	transferred	 into	100	mL	volumetric	
flask,	the	volume	was	completed	with	methanol	to	get	100.00	
µg/mL	 of	 SCG	 and	 25.00	 µg/mL	 of	 OXMT,	 and	 the	 prepared	
solution	 was	 filtered	 through	 0.45	 μm	 membrane	 filter.	 An	
appropriate	dilution	was	made	with	methanol	 to	prepare	 the	
working	 solution	 containing	 10.00	 µg/mL	 of	 SCG	 and	 2.50	
µg/mL	 of	 OXMT.	 Three	 replicates	 for	 each	 experiment	 were	
done.	 The	 concentrations	 of	 pure	 SCG	 and	 OXMT	 were	
calculated	 from	 their	 corresponding	 regression	 equations.	
When	carrying	out	 the	standard	addition	 technique,	different	
known	concentrations	of	pure	 standard	SCG	and	OXMT	were	
added	to	the	pharmaceutical	formulation	before	proceeding	in	
the	previously	mentioned	methods.	
	
3.	Results	and	discussion		
	
The	 aim	 of	 this	 work	 was	 to	 develop	 simple,	 sensitive,	
selective	 and	 precise	 spectrophotometric	 methods	 for	
simultaneous	 determination	 of	 binary	 mixture	 of	 SCG	 and	
OXMT	in	their	pure	form	and	pharmaceutical	formulation.	The	
absorption	spectra	of	SCG	and	OXMT	showed	a	sever	overlap	
in	the	region	200‐300	nm,	while	from	300‐400	nm	OXMT	had	
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no	 spectral	 contribution.	 This	 allowed	 the	 determination	 of	
SCG	at	λmax	=	320.6	nm	without	any	 interference	 from	OXMT,	
as	 shown	 in	 Figure	 2.	 However,	 SCG	 interfere	 with	 the	
determination	of	OXMT	which	necessitates	 the	 application	of	
spectral	manipulation	for	its	determination	through	removing	
the	interference	of	SCG.	
	
	
Figure	 2.	 Zero‐order	 spectra	 of	 sodium	 cromoglycate	 (—)	 and	
oxymetazoline	hydrochloride	(‐	‐	‐)	in	methanol,	10.00	µg/mL	each.	
	
	
3.1.	Determination	of	SCG	using	direct	spectrophotometry		
	
A	linear	relationship	was	obtained	between	absorbance	of	
SCG	at	320.6	nm	and	 the	 corresponding	 concentration	 in	 the	
range	 of	 (1.00‐25.00	 µg/mL).	 The	 linear	 regression	 equation	
was	found	to	be:	
	
A	=	0.0454C	+	0.0056	 r	=	1.0000	 	 (1)	
	
where	A	is	the	absorbance	at	320.6	nm,	C	is	the	concentration	
and	r	is	the	correlation	coefficient.	
	
3.2.	Determination	of	OXMT	
	
3.2.1.	Method	A:	First	derivative	spectrophotometric	
method	[D1]	
	
Figure	3	showed	the	 1D	spectra	 for	 the	 two	drugs,	where	
OXMT	exhibited	peak	maxima	at	289.2	nm,	while	SCG	did	not	
interfere.	The	wavelength	increment	over	which	the	derivative	
was	 obtained	 (Δλ)	 was	 carefully	 tested,	 Δλ	 =	 8	 and	 scaling	
factor	of	10	gave	a	suitable	signal	to	noise	ratio	and	the	spectra	
showed	 good	 resolution.	 A	 linear	 relationship	 was	 obtained	
between	 peak	 amplitude	 at	 the	 selected	wavelength	 and	 the	
corresponding	 concentration	 in	 the	 range	 of	 (4.00‐22.00	
µg/mL).	The	linear	regression	equation	was	found	to	be:	
	
P	=	0.0068C	+	0.0007		 r	=	0.9994	 	 (2)	
	
where	 P	 is	 the	 1D	 peak	 amplitude	 at	 289.2	 nm,	 C	 is	 the	
concentration	and	r	is	the	correlation	coefficient.	
	
	
	
Figure	 3.	 First	 derivative	 spectra	 1D	 of	 5.00	 μg/mL	 of	 oxymetazoline	
hydrochloride	 (—)	 and	 three	 different	 concentrations	 (5.00,	 10.00	 and	
15.00	μg/mL)	of	sodium	cromoglycate	(‐	‐	‐).	
	
3.2.2.	Method	B:	First	derivative	of	ratio	spectra	method	
[1DD]	
	
Figure	4	shows	the	1DD	spectra	using	SCG	(10.00	µg/mL)	
as	 a	 divisor,	 where	 OXMT	 shows	 a	 peak	maxima	 at	 292	 nm	
with	 no	 interference	 of	 SCG	 and	 the	 whole	 spectrum	 of	 the	
interfering	 substance	 is	 cancelled.	 Accordingly,	 the	 choice	 of	
the	wavelength	selected	for	calibration	is	not	critical	as	in	the	
1D	 method.	 The	 ratio	 spectra	 for	 OXMT	 (6.00‐22.00	 µg/mL)	
were	obtained	and	then	1DD	spectra	were	calculated.	A	linear	
relationship	was	obtained	between	peak	amplitude	at	λ	=	292	
nm	and	the	corresponding	concentration	in	the	range	of	6.00‐
22.00	µg/mL.	The	linear	regression	equation	was	found	to	be:	
	
P	=	0.0525C	‐	0.0028	 r	=	0.9999	 	 (3)	
	
where	 P	 is	 the	 1DD	 peak	 amplitude	 at	 292	 nm,	 C	 is	 the	
concentration	and	r	is	the	correlation	coefficient.	
	
	
	
Figure	4.	Ratio	(a)	and	first	derivative	of	ratio	spectra	1DD	(b)	of	6.00‐22.00	
μg/mL	of	oxymetazoline	hydrochloride,	using	sodium	cromoglycate	(10.00	
μg/mL)	as	a	divisor.	
	
3.2.3.	Method	C:	Ratio	difference	method	(RD)	
	
Several	 approaches	 have	 been	 developed	 to	 remove	 the	
overlapping	 constant	 in	 the	 ratio	 spectrum,	 either	 by	 using	
certain	order	derivative	or	through	a	sophisticated	subtraction	
followed	by	a	multiplication	procedure.	The	latter	was	capable	
of	 determining	 only	 the	 component	 with	 the	 less	 extended	
spectrum	 in	 the	 mixture	 [37].	 A	 simple	 innovative	 method	
namely	ratio	difference	was	developed	capable	of	determining	
OXMT	 in	 binary	 mixture	 with	 SCG	 with	 minimal	 data	
processing	 and	 high	 selectivity,	 regardless	which	 component	
has	 more	 extended	 spectrum	 [38‐41].	 The	 utility	 of	 ratio	
difference	method	 is	 to	 calculate	 the	unknown	concentration	
of	 a	 component	 of	 interest	 present	 in	 a	 mixture	 containing	
both	 component	 of	 interest	 and	 an	 unwanted	 interfering	
component.	
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For	 the	 determination	 of	 the	 concentration	 of	 the	
component	of	interest	by	the	ratio	difference	method,	the	only	
requirement	is	the	contribution	of	the	two	components	at	the	
two	selected	wavelengths	λ1	and	λ2,	where	the	ratio	spectrum	
of	 the	 interfering	 component	 shows	 the	 same	 amplitudes	
(constant)	 but	 the	 component	 of	 interest	 shows	 significant	
difference	in	these	two	amplitude	values	at	those	two	selected	
wavelengths	with	concentration.		
For	 the	 determination	 of	 OXMT,	 two	 wavelengths	 were	
selected	 (286.6	 and	 294.0	 nm),	 where	 the	 ratio	 spectrum	 of	
SCG	 showed	 the	 same	 amplitudes	 (constant)	 but	 the	 ratio	
spectrum	of	OXMT	showed	significant	difference	in	these	two	
amplitude	 values	 at	 these	 two	 selected	 wavelengths	 with	
concentration	 (Figure	 5).	 Correlation	 was	 obtained	 between	
ΔP	 286.6‐294.0	 nm	 and	 the	 corresponding	 concentration	 of	
OXMT.	The	respective	regression	equation	was	found	to	be:	
	
ΔP	286.6‐294	nm	=	0.0592	C‐	0.0027	 r	=	0.9999	 (4)	
	
where,	 ΔP	 286.6‐294.0	 nm	 is	 the	 difference	 in	 amplitude	 at	
286.6	and	294.0	nm,	C	is	the	concentration	in	μg/mL	and	r	is	
the	correlation	coefficient.	
	
	
Figure	 5.	 Ratio	 spectra	 of	 10.00	 μg/mL	 of	 each	 of	 oxymetazoline	
hydrochloride	 (‐	 ‐	 ‐)	 and	 sodium	 cromoglycate	 (—)	 using	 10.00	 μg/mL	
sodium	cromoglycate	as	a	divisor.	
	
3.2.4.	Method	D:	Ratio	subtraction	method	(RS)	
	
El‐Bardicy	 et	 al.	 [37]	 introduced	 the	 RS	 method	 which	
could	 be	 applied	 for	 determination	 of	 several	 drugs	 in	 their	
binary	mixtures	without	prior	 separation.	This	method	could	
be	applied	for	determination	of	binary	mixture	of	SCG	(X)	and	
OXMT	 (Y)	where	 the	 spectrum	of	 (X)	 is	more	 extended	 than	
the	 other	 component	 (Y),	 as	 shown	 in	 Figure	 2.	 The	
determination	of	(Y)	was	achieved	by	scanning	the	zero	order	
absorption	spectra	of	the	laboratory	prepared	mixtures	(X	and	
Y)	 in	 methanol,	 then	 dividing	 them	 by	 a	 carefully	 chosen	
concentration	 (10.00	 µg/mL)	 of	 standard	 (X)	 using	 X0	 as	 a	
divisor	to	produce	a	new	ratio	spectra	that	represents	Y/X0	+	
X/X0	 (constant),	 as	 shown	 in	 Figure	 6.	 The	 constant	 value	
could	 be	 determined	 directly	 from	 the	 curve	 by	 the	 plateau	
straight	 line	 (300‐350	 nm)	 which	 was	 parallel	 to	 the	
wavelength	 axis	 in	 the	 region	where	 (X)	was	 extended;	 then	
subtraction	of	the	absorbance	values	of	these	constants	(X/X0)	
in	 plateau;	 (Figure	 7),	 followed	 by	 multiplication	 of	 the	
obtained	 spectra	 by	 the	 divisor	 (X0).	 Finally,	 the	 original	
spectra	of	(Y)	could	be	obtained,	(Figure	8)	and	were	used	for	
direct	determination	of	(Y)	at	282.6	nm	in	the	mixtures	in	the	
concentration	 range	 of	 4.00‐22.00	 µg/mL,	 while	 the	
concentration	 of	 (X)	 could	 be	 calculated	 without	 any	
interference,	 at	 its	 λmax	 320.6	 nm.	 A	 linear	 relationship	 was	
obtained	 between	 absorbance	 of	OXMT	 at	 λ	 =	 282.6	 nm	 and	
the	 corresponding	 concentration	 in	 the	 range	 of	 4.00‐22.00	
µg/mL.	The	linear	regression	was	found	to	be:	
	
A	=	0.0385	C	–	0.0015	 r	=	0.9999	 	 (5)	
	
	
where	A	is	the	absorbance	at	282.6	nm,	C	is	the	concentration	
and	r	is	the	correlation	coefficient.	
	
	
 
Figure	 6.	 Ratio	 spectra	 of	 different	 lab	 mixtures	 of	 oxymetazoline	
hydrochloride	 and	 sodium	 cromoglycate	 using	 10.00	 μg/mL	 sodium	
cromoglycate as	a	divisor.
	
	
Figure	 7.	 Ratio	 spectra	 of	 different	 lab	 mixtures	 of	 oxymetazoline	
hydrochloride	 and	 sodium	 cromoglycate	 using10.00	 μg/mL	 sodium	
cromoglycate	as	a	divisor	after	subtraction	of	the	constant	at	plateau.	
	
	
Figure	 8.	 Ratio	 spectra	 of	 different	 lab	 mixtures	 of	 oxymetazoline	
hydrochloride	and	sodium	cromoglycate	using	10.00	μg/mL	SCG	as	a	divisor	
after	subtraction	of	the	constant	at	plateaufollowed	by	multiplication	of	the	
obtained	spectra	by	the	divisor.	
	
This	 method	 showed	 maximum	 accuracy	 and	
reproducibility	 over	 the	 other	 methods	 since	 it	 obtains	 the	
original	spectra	of	the	component	in	the	binary	mixture	in	its	
zero	 order	 and	 allows	 its	 determination	 at	 its	 λmax.	 On	 the	
other	hand,	 the	disadvantage	 is	that	 it	requires	 the	extension	
of	one	of	the	two	components	of	the	mixture.	Thus,	it	is	limited	
to	determination	of	the	non‐extended	component	only.		
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Table	1.	Assay	parameters	and	method	validation	obtained	by	applying	the	proposed	spectrophotometric	methods	for	determination	of	sodium	cromoglycate	
(SCG)	and	oxymetazoline	hydrochloride	(OXMT)	in	binary	mixtures.	
Method	 SCG	 OXMT
[0D]	method	
λ	=	320.6	nm	
[1D]	method	
λ	=	289.2	nm	
[1DD]	
λ	=	292.0	nm	
[RDSM]	
(ΔP	286.6‐294.0	nm)	
[RSM] 
λ	=	282.6	nm	
Calibration	range	(µg/mL)	 1.00‐25.00	 4.00‐22.00 4.00‐22.00 6.00‐22.00 4.00‐22.00
Slope	 0.0454	 0.0083 0.0592 0.0525 0.0068
Intercept	 0.0056	 0.0027 ‐ 0.0027 ‐ 0.0028 0.0007
r	 1.0000	 0.9995 0.9999 0.9999 0.9994
LOD	(µg/mL)	 0.24	 0.53	 0.41	 0.77	 0.46	
LOQ	(µg/mL)	 0.68	 1.60	 1.24	 2.31	 1.39	
Accuracy	(Mean±RSD	)	*	 99.86±1.602	 101.01±1.248	 99.79±0.985	 100.36±1.086	 99.69±1.487	
Precision	(RSD	)	 0.540	 1.000 1.020 1.107 0.932
Repeatability	intermediate	precision		 0.613	 0.459 0.987 1.122 0.732
*Average	of	three	determinations.	
	
Table	 2.	 Determination	 of	 sodium	 cromoglycate	 (SCG)	 and	 oxymetazoline	 hydrochloride	 (OXMT)	 in	 laboratory	 prepared	 mixtures	 by	 the	 proposed	
spectrophotometric	methods.	
Concentration	(μg/mL)	 SCG	 OXMT	
SCG	 OXMT	 [0D]	
λ	=	320.6	nm	
[1D] 
λ	=	289.2	nm	
[1DD] 
λ	=	292.0	nm	
[RDSM] 
(ΔP	286.6‐294.0	nm)	
[RSM] 
λ	=	282.6	nm	
12.00	 4.00	 98.18	 98.74	 102.09	 ‐	 99.16	
2.00	 10.00	 99.93	 98.18	 102.04	 98.45	 98.74	
4.00	 8.00	 99.15	 98.77 98.74 98.18 98.77
12.00	 16.00	 100.67	 99.12 98.77 102.11 99.93
6.00	 18.00	 102.01	 99.15 99.15 100.67 100.60
24.00	 6.00	 100.60	 98.77 100.00 100.97 98.19
*	Mean±RSD	 100.09±1.331	 98.79±0.346 100.13±1.567 100.08±1.699	 99.23±0.877
*Average	of	three	determinations.	
	
Table	 3.	 Determination	 of	 sodium	 cromoglycate	 (SCG)	 and	 oxymetazoline	 hydrochloride	 (OXMT)	 in	 Nasocrom®	 nasal	 spray	 by	 the	 proposed	
spectrophotometric	methods	and	the	application	of	standard	addition	technique.	
Method	 SCG OXMT	
[0D] 
λ	=	320.6	nm	
[1D] 
λ	=	289.2	nm	
[1DD] 
λ	=	292	nm	
[RDSM]
(ΔP	286.6‐294	nm)	
[RSM] 
λ	=	282.6	nm	
Nasocrom	nasal	spray	B.N.	11087	* 103.31±1.991	 99.08±0.733 100.82±1.775 102.08±1.733	 102.00±0.000
Recovery%	of	standard	added	 99.97±1.431	 98.25±1.313 99.75±0.712 100.09±1.136	 99.77±1.719
*	Claimed	to	contain	2	g	SCG	and	0.025	g	OXMT	per	100	mL.	
	
	
Another	 drawback	 was	 observed	 upon	 analysis	 of	
mixtures	 containing	 low	concentrations	of	 the	divisor,	where	
the	 calculation	 of	 the	 constant	 value	 through	 plateau	 region	
was	critical	due	to	low	signal	to	noise	ratio.	
	
3.3.	Method	validation	
	
Validation	was	done	according	to	ICH	guidelines	[42].	
	
3.3.1.	Linearity	
	
The	 linear	 regression	 data	 for	 the	 calibration	 curves	
showed	good	linear	relationships.	The	correlation	coefficients	
for	 the	 five	proposed	methods	ranged	 from	0.9994	 to	1.0000	
as	summarized	in	Table	1.	
	
3.3.2.	Accuracy	
	
The	accuracy	of	the	five	methods	was	tested	by	analyzing	
freshly	prepared	 solutions	 of	 the	 two	drugs	 (7.50,	 10.00	 and	
12.50	µg/mL)	in	triplicate.	The	percentage	recoveries	for	each	
drug	were	calculated	and	summarized	in	Table	1.	
	
3.3.3.	Range	
	
The	 calibration	 range	 was	 established	 through	
considerations	 of	 the	 practical	 range	 necessary	 according	 to	
adherence	 to	 Beer’s	 law	 and	 the	 concentration	 of	 SCG	 and	
OXMT	 present	 in	 the	 pharmaceutical	 preparation	 to	 give	
accurate	precise	and	linear	results	(Table	1).	
	
3.3.4.	Precision	
	
Three	 concentrations	 of	 SCG	 and	OXMT	 (7.50,	 10.00	 and	
12.50	µg/mL)	were	analyzed	in	triplicate	in	the	same	day	and	
in	three	successive	days	using	the	proposed	methods	in	order	
to	 determine	 the	 Repeatability	 and	 Intermediate	 precision,	
respectively.	 Relative	 standard	 deviation	 (RSD)	 values	 were	
calculated	for	each	sample	and	summarized	in	Table	1.	
	
3.3.5.	Specificity	
	
The	 specificity	 of	 the	 methods	 was	 assessed	 by	 the	
analysis	of	different	laboratory	prepared	mixtures	of	SCG	and	
OXMT	 within	 the	 linearity	 range.	 Satisfactory	 results	 were	
obtained	as	shown	in	Table	2.	
	
3.4.	Application	to	Nasocrom®	nasal	spray	and	standard	
addition	
	
The	 five	proposed	methods	were	 successfully	 applied	 for	
the	 determination	 of	 the	 studied	 drugs	 in	 their	 nasal	 spray	
dosage	 form.	 The	 results	 which	 are	 average	 of	 three	
determinations	 are	 shown	 in	 Table	 3.	 The	 validity	 of	 the	
proposed	 methods	 was	 further	 assessed	 by	 applying	 the	
standard	 addition	 technique	 for	 the	 analysis	 of	 Nasocrom®	
nasal	spray	and	results	were	summarized	in	Table	3.	
	
3.5.	Statistical	analysis	
	
Results	 obtained	 from	 the	 proposed	 methods	 were	
statistically	 compared	 to	 those	obtained	by	 applying	 the	USP	
methods	[36]	which	are	spectrophotometric	method	and	HPLC	
for	SCG	and	OXMT,	respectively.	Results	showed	no	significant	
difference	 as	 observed	 from	 the	 calculated	 t	 and	 F	 values	
(Table	4).	To	compare	the	ability	of	the	proposed	methods	for	
the	determination	of	OXMT,	 the	 results	 obtained	by	 applying	
the	 proposed	 methods	 were	 subjected	 to	 statistical	 analysis	
using	one	way	ANOVA	test,	there	was	no	significant	difference	
(F	 <	 Fcrit)	 between	 all	 the	 proposed	methods	 and	 the	 official	
one	[36]	1as	summarized	in	Table	5.	
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Table	4.	Statistical	analysis	of	the	proposed	methods	and	Official	method	for	sodium	cromoglycate	(SCG)	and	oxymetazoline	hydrochloride	(OXMT)	in	their	
pure	powder	form.	
Method	 SCG	 OXMT
Official		
method	a	
[0D]	
λ	=	320.6	nm	
[1D]
λ	=	289.2	nm	
[1DD] 
λ	=	292	nm	
[RDSM] 
(ΔP	286.6‐294.0	nm)	
[RSM] 
λ	=	282.6	nm	
Official
method	b	
Mean	 101.50	 99.86	 101.01 99.79 100.36 99.69	 99.93
S.D	 1.005	 1.600	 1.261 0.983 1.090 1.482	 1.005
Variance	 1.010	 2.561	 1.589 0.966 1.188 2.196	 1.010
n	 5	 5	 5 5 5 5	 5
Student's	t‐test	(2.306)	c	 ‐	 1.939	 1.499 0.222 0.645 0.306	 ‐	
F‐value	(6.388)	c	 ‐	 2.535	 1.573	 0.957	 1.176	 2.175	 ‐	
a	Direct	absorbance	measurement	at	λmax	326	nm	using	Sodium	phosphate	buffer	(pH	=	7.4)	as	a	blank	[36].	1	
b	HPLC	method;	mobile	phase:	water:	methanol:	1	M	sodium	acetate:	glacial	acetic	acid	(46:40:10:4)	with	UV	detection	at	280	nm	[36].		1.	
c	Figures	in	parentheses	are	the	corresponding	tabulated	values	at	p	=	0.05.	
	
Table	5.	Results	of	ANOVA	(one	way)	for	comparison	of	the	proposed	methods	and	the	official	one	for	determination	of	oxymetazoline	hydrochloride.	
Source	of	variation	 SS	 df MS F p‐value	 F	crit.
Between	groups	 5.873	 4.000	 1.468	 1.052	 0.406	 2.866	
Within	groups	 27.911	 20.000 1.396
Total	 33.784	 24.000	
Official	method:	HPLC	method;	mobile	phase:	water:	methanol:	1	M	sodium	acetate:	glacial	acetic	acid	(46:40:10:4)	with	UV	detection	at	280	nm	[36].	1.	
	
	
4.	Conclusion	
	
We	can	conclude	that	the	proposed	methods	are	accurate,	
sensitive,	 selective	 and	precise.	 Furthermore	 they	 are	 simple	
and	 do	 not	 require	 any	 sophisticated	 techniques	 or	
instruments.	Therefore	they	are	effective	methods	that	can	be	
used	 for	 the	 routine	 analysis	 of	 SCG	 and	OXMT	 in	 their	 pure	
forms	 and	 in	 their	 available	 dosage	 form	 without	 prior	
separation.	
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